MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Update

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 437,032 shares, a growth of 31.6% from the March 15th total of 332,123 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average trading volume of 186,097 shares, the days-to-cover ratio is presently 2.3 days.

Analysts Set New Price Targets

A number of research firms recently issued reports on MIRA. Rodman & Renshaw began coverage on shares of MIRA Pharmaceuticals in a research report on Tuesday, January 13th. They set a “buy” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research note on Friday, March 27th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold”.

MIRA Pharmaceuticals Price Performance

NASDAQ:MIRA traded up $0.02 during trading hours on Thursday, reaching $1.05. The company had a trading volume of 317,989 shares, compared to its average volume of 166,904. MIRA Pharmaceuticals has a 1-year low of $0.83 and a 1-year high of $2.45. The firm has a market cap of $44.12 million, a PE ratio of -0.69 and a beta of 1.91. The business’s 50 day moving average price is $1.14 and its 200-day moving average price is $1.34.

Hedge Funds Weigh In On MIRA Pharmaceuticals

Several institutional investors have recently made changes to their positions in MIRA. First American Bank grew its position in MIRA Pharmaceuticals by 20.0% during the fourth quarter. First American Bank now owns 60,000 shares of the company’s stock valued at $91,000 after buying an additional 10,000 shares during the period. Fifth Third Bancorp acquired a new position in shares of MIRA Pharmaceuticals in the fourth quarter worth about $30,000. XTX Topco Ltd purchased a new stake in shares of MIRA Pharmaceuticals during the 2nd quarter worth about $26,000. Creative Planning purchased a new stake in shares of MIRA Pharmaceuticals during the 2nd quarter worth about $27,000. Finally, Two Sigma Investments LP grew its position in shares of MIRA Pharmaceuticals by 129.8% during the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after acquiring an additional 25,816 shares during the period. 35.16% of the stock is owned by hedge funds and other institutional investors.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.